Navigation Links
Experimental treatment protects monkeys from lethal Ebola virus post-exposure
Date:5/28/2010

Scientists using tiny particles of genetic material to interfere in the replication process of the deadly Ebola virus have successfully prevented monkeys exposed to that virus from dying of hemorrhagic fever. The proof-of-concept study, published in this week's issue of The Lancet, suggests that such protection also should be possible in humans.

"Over the past decade, we have evaluated numerous therapeutic approaches for the treatment of lethal viruses, such as Ebola," said co-author Dr. Lisa E. Hensley of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). "None of them have conferred complete protection to Ebola virus-infected primatesuntil now."

Using particles called small interfering RNAs (siRNAs), the authors targeted a protein (called the L protein) that is essential for Ebola virus replication. RNA inhibitors, as they are commonly called, are based on a natural gene silencing mechanism used by all cells, and RNAi therapeutics rely on a delivery technology to be effective.

Lipid nanoparticles (LNPs) are the most widely used siRNA delivery approaches. In this study, the research team used a proprietary technology called SNALP, or stable nucleic acid-lipid particles, to deliver the therapeutics to disease sites in animal models infected with the Zaire strain of Ebola virus (ZEBOV).

A group of three rhesus macaques was given anti-ZEBOV siRNAs intravenously, 30 minutes after exposure to the virus, and again on days 1, 3, and 5. A second group of four macaques was given the treatment after 30 minutes, and on days 1, 2, 3, 4, 5, and 6, after challenge with ZEBOV.

Two of the three animals in the first group (which received four post-exposure treatments) were protected from lethal ZEBOV infection and survived. All four of the monkeys given seven post-exposure treatments were protected. The treatment regimen in the second study was well tolerated, with minor changes in liver enzymes that might have been related to viral infection.

The study represents the first demonstration of complete protection against a lethal human infectious disease in nonhuman primates using RNAi, according to lead author Dr. Thomas W. Geisbert of the Boston University School of Medicine.

"We believe this work justifies the immediate development of Ebola SNALP as a countermeasure to treat Ebola infected patients, either in outbreaks or accidental laboratory exposures," he said.

Ebola virus causes hemorrhagic fever with case fatality rates as high as 80 percent in humans. The virus, which is infectious by aerosol (although more commonly spread through blood and bodily fluids of infected patients), is of concern both as a global health threat and a potential agent of biological warfare or terrorism.

Currently there are no available vaccines or therapies, so researchers working with Ebola virus must do so in maximum containment (Biosafety Level 4) laboratories. In these specially designed laboratories, investigators wear positive pressure "space suits" and breathe filtered air as they work, and all laboratory waste streams are sterilized.

The SNALP-RNAi therapeutic used in the study was developed by Tekmira Pharmaceuticals Corporation of Vancouver, BC. Previous research showed that these siRNAs completely protected guinea pigs when administered shortly after a lethal dose of ZEBOV was administered. While rodent studies are useful for screening prospective medical countermeasures, they are frequently not useful for prediction of efficacy in the more stringent non-human primate models.

Further studies in monkeys would be necessary to refine dosing, toxicology and other issued before the treatment could be licensed for human use.

"The significance of this report goes beyond the protection against Ebola virus," said COL John P. Skvorak, commander of USAMRIID. "It also represents the potential for this concept to be applied to other viral infections."


'/>"/>

Contact: Caree Vander Linden
caree.vanderlinden@us.army.mil
301-619-2285
US Army Medical Research Institute of Infectious Diseases
Source:Eurekalert

Related biology news :

1. Experimental Biology 2008 meets in San Diego April 5-9
2. Translational research patented first experimental treatment against idiopathic pulmonary fibrosis
3. Experimental Biology and Medicine announces expansion into Asia, opens new office
4. Experimental chemotherapy regimen shows promise in treating advanced lung cancer
5. French scientist wins the Journal of Experimental Biology Outstanding Paper Prize
6. Survival in a Changing World: The Journal of Experimental Biology 2009 symposium
7. 40 minority scientists receive travel fellowships to Experimental Biology 2009 in New Orleans
8. Experimental treatment halts hypoxic-ischemic brain injury in newborns
9. Experimental treatments restore partial vision to blind people
10. Experimental drug shows promise against brain, prostate cancers
11. French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/2/2017)... 2017  EyeLock LLC, a market leader of iris-based ... " What You Should Know About Biometrics in the ... authenticity is a growing concern. In traditional schemes, cryptography ... traditional authentication schemes such as username/password suffer from inherent ... offers an elegant solution to the problem of high-security ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... Francisco, CA (PRWEB) , ... February 20, 2017 ... ... reduce infections in patients with catheters associated with peritoneal dialysis, announced today that ... light-based peritoneal dialysis catheter connection system in Peritoneal Dialysis International (PDI), the ...
(Date:2/19/2017)... ... February 19, 2017 , ... Expanding Portfolio to Include ... weighing equipment with the goal of expanding the reach of its quality and ... Starter water analysis meters were introduced into the market in 2014. , The ...
(Date:2/18/2017)... Research and Markets has announced the addition of the ... ... provides separate comprehensive analytics for the US, Japan ... estimates and forecasts are provided for the period 2015 through 2022. ... data and analytics are derived from primary and secondary research. This ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... flying hobbyists, and DJI, the world’s leading maker of unmanned aircraft systems (UAS), ... public safety officers to use drones effectively, and support educational outreach efforts. , ...
Breaking Biology Technology: